INTRODUCTION
Hereditary nonpolyposis colorectal cancer (HNPCC) (MIM#-120435), also known as Lynch syndrome, is the most common known form of hereditary colorectal cancer (CRC) (1) . It accounts for approximately 2-5% of all the colorectal cancer cases (2) . It is an autosomal dominant inheritance syndrome associated with heritable defects in DNA mismatch repair genes (MMR). HNPCC is characterized by earlier onset of colorectal cancer, proximal colonic cancer predominance, and an increased incidence of cancer in extracolonic organs such as endometrial, stomach, ovary, small bowel, hepatobiliary tract, renal pelvis, ureter, skin, and brain (3, 4) . Germline mutations in at least 5 DNA mismatch-repair genes (MMR) cause HNPCC: MLH1 (3p21-23) (MIM*120436), MSH2 (2p21) (MIM*609309), MSH6 (2p21) (MIM*600678), PMS1 (2q31-q33) (MIM*600258), and PMS2 (7p22) (MIM*600259). Most (90%) of the mutations were found in two MMR genes: MLH1 (50%) and MSH2 (40%), whereas 7% mutations occurred in MSH6 and 3% for the remaining genes (5) . The Amsterdam criteria were established by the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC) in 1990. As the widely accepted criteria for diagnosis of HNPCC, it has some limitations. It is too restrictive and difficult to identify HNPCC cases in small family (2) . Thus, some other guidelines, such as Bethesda criteria, were also formed to identify suspected patients (6) . The golden standard for diagnostic of HNPCC is germline mutation in MMR genes. At present, direct sequencing is the key procedure in recognizing MMR genes defects. As most studies of HNPCC are limited in race and sample sizes, several MMR gene mutation databases were established to share data around the world. The most authoritative one is InSiGHT (http://www.insight-group.org/mutations/), set up by the International Society of Gastrointestinal Hereditary Tumors. InSiGHT collected a large amount of data on MLH1 and MSH2 genes. The total number of variants for MLH1 was 6079, and for MSH2 was 4428 (accessed in May 2010). Also there is a database with unclassified variants (www.mmruv.info) supporting the InSiGHT. Our previous studies based on InSiGHT suggested there were differences in MLH1 and MSH2 mutations between Caucasian and Asian populations (7) . In the meantime, Sheng et al. indicated Kong, was more than Western countries (8) . A predominance of distal tumors (9) and primary extracolonic tumors in stomach (10) in Asian HNPCC patients were reported, which were also different from those in Western countries. Kim et al. found the three novel germline mutations in MLH1 and MSH2 in Korea (11) . The study was to analyze MLH1 and MSH2 mutations in 98 unrelated probands of the suspected HNPCC families, which is one of the large scale studies in Chinese population. In addition to those reported, several novel MLH1 and MSH2 mutations and a suspected hotspot in the group of Chinese HNPCC patients were identified.
RESULTS
A total of eleven mutations were found in ten patients (11%) from the 98 probands, with six in MLH1 (54.5%) and five in MSH2 (45.5%) genes (Table 1) . Four families who met the Amsterdam criteria harbored mutations, and six families who met Bethesda criteria had mutations. Three novel mutations which had never been reported were founded in patients H76 (MLH1 c.157_160delGAGG), H86 (MLH1 c.-64G＞T) and H224 (MLH1 c.2157dupT). There were five mutations previously reported, including one known polymorphism in MLH1 c.655A＞G (dsSNP1799977). Interestingly, c.1168C＞T of MSH2, a missense mutation, was found in four unrelated probands (H88, H224, H231 and H245). Furthermore, one patient (H224) was a compound heterozygote for a novel pathogenic frameshift mutation in MLH1 and a missense mutation in MSH2.
Patient H86
Sequence analysis of MLH1 revealed a novel G＞T substitution at nucleotide -64 (Fig. 1a) , which is in the promoter area. It may result in alteration or loss of MLH1 gene function. No mutation was identified in MSH2.
Patient H76
Sequence analysis of MLH1 coding area revealed the deletion of four nucleotides GAGG at 157_160 in exon 2 (Fig. 1b) . This deletion caused a frameshift mutation, results in the replacement of a Gly with an Ala at codon 54, and early termination at two amino acids after. Comprehensive sequence analysis of MLH1 and MSH2 genes revealed no other mutations.
Patient H224
An insertion (c.2157dupT, Fig. 1c ) in MLH1 was found in patient H224, which resulted in a frameshift mutation and replacement of Val with Cys at codon 720, and ended in three amino acids. Meanwhile, a C＞T substitution at nucleotide 1168, resulted in the replacement of a phenylalanine-encoding codon with a leucine-encoding codon at codon 390 in MSH2 gene.
DISCUSSION
In this study, eleven germline mutations were found in ten probands. Among them were eight distinct mutations, all of which were heterozygote. Although some researchers found bi-allelic mutations in HNPCC patients, most alterations are mono-allelic. Among the eight germline mutations we identified, four are missense mutations, two are frameshift mutations, one is aberrant splicing, and one is in promoter area. Missense mutations are also the common mutation type in Chinese population. The missense mutations (MLH1 c.655A＞G, MLH1 c.2042C＞T, MSH2 c.23C＞T and MSH2 c.1168C＞T) were identified as "missense mutations of unknown significance", functions of which were controversial. Four probands had one same mutation -MSH2 c.1168C＞T (p.L390P). We searched for MSH2 c.1168C＞T in InSiGHT database and the original papers, and found the mutations (about 80%) frequently occurred in East Asia populations, including http://bmbreports.org BMB reports Chinese Han, Japanese, Korean and Singaporean (Fig. 2) . However, in a study of 1721 German suspected HNPCC families, Mangold detected no instance of MSH2 c.1168C＞T (12) . Although this mutation was first reported by Konishi in 1996, its function is still controversial (13). Banno et al. found this mutation in two out of eleven (18%) endometrial cancer patients who had family histories of colorectal and endometrial carcinoma. Later, a high occurrence rate (7%) of the mutation was observed among 179 healthy Japanese individuals, so it was reported to be a polymorphorism but not a causative mutation for CRC (14) . Kim et al. also reported this mutation as SNP in healthy Korean individuals, which showed no association with sporadic colorectal cancer (15) , and was recently identified as SNP (dsSNP17224367). However, Chen et al. suggested this mutation might cause a polarity change at the margin of the interaction region of MSH2 (16). Fan et al. analyzed molecular epidemiologic, structural, bioinformatic and functional information of MSH2 c.1168C＞T. They found this variant in 4.89% of CRC and only in one healthy individual (0.89%). This variant resulted in a phenotype relevant to young sporadic CRC or GC, which was suspected as predisposing factor to gastrointestinal cancer (17) . In the same year, Zhang et al. found significant difference in the frequency of MSH2 c.1168C＞T between young-age patients and control individuals, and considered this mutation associated with an increased GC risk (18) . In our study the incidence of MSH2 c.1168C＞T is up to 4% in 98 HNPCC probands. This result is different from those Japanese and Korean studies. In Chinese study, incidence of MSH2 c.1168C＞T is much higher in patients than in controls. MLH1 c.655A＞G mutation was reported 224 times in InSiGHT database. In our study, one patient who fulfilled the Amsterdam criteria harbor MLH1 c.655A＞G mutation. The significance of the sequence alteration is controversial. The c.655A＞G variant is considered a polymorphism (dsSNP1799977) and was reported in HapMap database (www.hapmap.org). MLH1 c.655A＞G is in a conserved region of exon 8, and both alleles result in non-polar and pH-neutral amino acids. Functional analyses suggest that the variant has DNA repair efficiency (19, 20) and binding properties to PMS2 are similar to the wild type (21 (24) . The association was extended to CRC patients by Nejda et al., who showed patients with this variant displayed a better outcome in sporadic colorectal cancer (25) . This variant is not only involved in colorectal cancer, but also in some other types of cancers. MLH1 c.655A＞G was associated with an almost fivefold increased risk of ulcerative colitis (26) , and 6-to 16-fold increased risk of acute lymphoblastic leukaemia when combined with known genotypes of increased susceptibility to leukeamia (27) . The variant may be associated with the young-onset of lung cancer, especially in histological squamous cell type (28) , and may influence the disease onset of prostate cancer (29). Our results suggest a possible role of MLH1 c.655A＞G polymorphism in the Chinese HNPCC group, and it remains to be further investigated with additional samples.
We found three novel germline mutations. Two of these novel mutations caused frameshift mutations in MLH1 gene (H76 and H224) and made the coding terminate earlier. Both of them were considered as pathogenic. The other one (H86) was found in the promoter area of MLH1 (c.-64G＞T). Previous researches found connection between mutations in promoter area and diseases. The most frequent one in MLH1 gene is c.−93G＞A, While it is considered a SNP, some researchers noticed it was associated with CRC. (33) .
So this novel mutation we found in MLH1 promoter area may impair MLH1 protein function and may be associated with HNPCC.
We described one proband (H224) fulfilling Bethesda criteria with two different mutations in MLH1 and MSH2 -one was a novel pathogenic frameshift mutation MLH1 c.2157 dupT, and the other one was a missense mutation MSH2 c.1168C＞T. Such rare case of double mutations was reported before by others, in which patients were found to have two alterations in both MLH1 and MSH2 genes, and in most of the cases, one was a deletion and the other one was a point mutation (34). 
MATERIALS AND METHODS

Patients
Extraction of DNA from blood
Blood samples were taken from 98 probands. Genomic DNA was isolated from peripheral blood lymphocytes according to the manufacturer's instructions (TIANGEN BIOTECH, BEIJING). The extracted genomic DNA was stored at −20 o C for further analysis.
Mutation of MLH1 and MSH2 genes
Exons 1-19 of MLH1 and exons 1-16 of MSH2, including the splice-site junctions, were amplified by polymerase chain reaction (TaKaKa Biotechnology, Dalian). The PCR products were purified by 1.5% agarose gel electrophoresis, following the manufacturer's instructions (TIANGEN BIOTECH, BEIJING). All the purified products were sequenced by Shanghai Sunny Biotechnology Co., Ltd with 3730XL of ABI. Each mutation was amplified both the sense and antisense strand, and then the experiment was repeated at least once. If the mutation was exactly the same through at least three repeated experiments, the mutation was confirmed. By comparing with the reference sequences, missense and frameshift mutations were identified. We submitted eleven mutations, six from MLH1 and five from MSH2 gene from ten patients to InSiGHT database (http:// www.insight-group.org/mutations/). The IDs of the three novel mutations are: MLH1-01495, MLH1-01496, and MLH1-01497.
Definition of pathogenic mutations
Sequence variants which would obviously impact the function of MLH1 or MSH2 proteins, such as nonsense and frameshift mutations, were considered pathogenic. Besides, the mutations at highly conserved splice sites were also considered pathogenic. All the missense mutations were assessed for pathogenicity by searching against the InSiGHT database (http:// www.insight-group.org/mutations/), MMR Gene Unclassified Variants Database (www.mmruv.info), Mismatch Repair Genes Variants Database (www.med.mun.ca/MMRvariants), and the Human Gene Mutation Database (www.hgmd.cf.ac.uk/ac). If the missense mutations affected the promoter site, or have been reported as pathogenic mutations in other studies, they were also considered pathogenic. Those missense mutations whose pathogenicity could not be confirmed were classified as uncertain.
